[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2021002409A1 - Composiciones y métodos para tratar el cáncer - Google Patents

Composiciones y métodos para tratar el cáncer

Info

Publication number
CL2021002409A1
CL2021002409A1 CL2021002409A CL2021002409A CL2021002409A1 CL 2021002409 A1 CL2021002409 A1 CL 2021002409A1 CL 2021002409 A CL2021002409 A CL 2021002409A CL 2021002409 A CL2021002409 A CL 2021002409A CL 2021002409 A1 CL2021002409 A1 CL 2021002409A1
Authority
CL
Chile
Prior art keywords
methods
compositions
treating cancer
egfr
cytoplasmic
Prior art date
Application number
CL2021002409A
Other languages
English (en)
Inventor
David A Nathanson
Michael E Jung
Jonathan Tsang
Lorenz Urner
Peter M Clark
Timothy F Cloughesy
Gyudong Kim
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of CL2021002409A1 publication Critical patent/CL2021002409A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención describe compuestos que son capaces de penetrar hasta la barrera hematoencefálica para modular la actividad de la tirosina cinasa EGFR; métodos para tratar el glioblastoma y otros cánceres mediados por EGFR; y métodos para administrarle a un sujeto un inhibidor del metabolismo de la glucosa y un estabilizador de p53 citoplasmática.
CL2021002409A 2019-03-15 2021-09-15 Composiciones y métodos para tratar el cáncer CL2021002409A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962819322P 2019-03-15 2019-03-15
US201962904241P 2019-09-23 2019-09-23

Publications (1)

Publication Number Publication Date
CL2021002409A1 true CL2021002409A1 (es) 2022-06-17

Family

ID=72521289

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002409A CL2021002409A1 (es) 2019-03-15 2021-09-15 Composiciones y métodos para tratar el cáncer

Country Status (16)

Country Link
US (2) US11377451B2 (es)
EP (1) EP3938354A4 (es)
JP (2) JP7474269B2 (es)
KR (1) KR20210151820A (es)
CN (2) CN115215808A (es)
AU (1) AU2020241703A1 (es)
BR (1) BR112021018295A2 (es)
CA (1) CA3133688A1 (es)
CL (1) CL2021002409A1 (es)
CO (1) CO2021013496A2 (es)
CR (1) CR20210498A (es)
IL (1) IL286350A (es)
MX (1) MX2021011272A (es)
SA (1) SA521430328B1 (es)
SG (1) SG11202109662YA (es)
WO (1) WO2020190765A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200078495A (ko) * 2017-09-26 2020-07-01 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 조성물 및 방법
CN115215808A (zh) 2019-03-15 2022-10-21 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
US20230364091A1 (en) * 2020-09-21 2023-11-16 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022061299A1 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
WO2022061202A1 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022155311A1 (en) * 2021-01-14 2022-07-21 The Regents Of The University Of California Methods and systems for analysis of drug target engagement and treatment of cancer
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
WO2022240583A1 (en) * 2021-05-12 2022-11-17 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN113307799B (zh) * 2021-05-21 2022-07-19 大连医科大学 一种检测葡萄糖醛酸转移酶1a1荧光探针及其应用
IL311616A (en) * 2021-09-23 2024-05-01 Blatter Fritz EGFR inhibitory polymorph forms
WO2023244639A1 (en) * 2022-06-14 2023-12-21 The Regents Of The University Of California Methods of predicting cns cancer response to treatment with egfr inhibitors
WO2024081447A1 (en) * 2022-10-14 2024-04-18 The Regents Of The University Of California Egfr inhibitors for treating lung cancer
WO2024102177A1 (en) * 2022-11-08 2024-05-16 The Regents Of The University Of California Combination therapies for the treatment of brain cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
CN1854130B (zh) 2005-04-15 2011-04-20 中国医学科学院药物研究所 喹唑啉衍生物、及其制法和药物组合物与用途
WO2008046242A1 (fr) 2006-10-16 2008-04-24 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations
WO2011035540A1 (zh) 2009-09-28 2011-03-31 齐鲁制药有限公司 作为酪氨酸激酶抑制剂的4-（取代苯胺基）喹唑啉衍生物
ITPD20110091A1 (it) 2011-03-24 2012-09-25 Univ Padova Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico.
US10206924B2 (en) * 2014-12-15 2019-02-19 The Regents Of The University Of Michigan Small molecule inhibitors of EGFR and PI3K
CN105017163A (zh) 2015-08-25 2015-11-04 佛山市赛维斯医药科技有限公司 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途
US10473255B2 (en) 2015-12-29 2019-11-12 Ge-Hitachi Nuclear Energy Americas Llc Reactor pressure vessel including pipe restraint device, and/or a pipe restraint device
AU2017204973A1 (en) 2016-01-06 2018-07-12 Trillium Therapeutics Inc. Novel fluorinated quinazoline derivatives as EGFR inhibitors
CN106432202B (zh) 2016-09-22 2019-04-02 郑州大学第一附属医院 喹唑啉类衍生物及其应用
KR20200078495A (ko) * 2017-09-26 2020-07-01 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 조성물 및 방법
CN115215808A (zh) 2019-03-15 2022-10-21 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
US20230364091A1 (en) 2020-09-21 2023-11-16 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022061202A1 (en) 2020-09-21 2022-03-24 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022061299A1 (en) 2020-09-21 2022-03-24 The Regents Of The University Of California Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
IL311616A (en) 2021-09-23 2024-05-01 Blatter Fritz EGFR inhibitory polymorph forms
WO2023244639A1 (en) 2022-06-14 2023-12-21 The Regents Of The University Of California Methods of predicting cns cancer response to treatment with egfr inhibitors

Also Published As

Publication number Publication date
US11377451B2 (en) 2022-07-05
CO2021013496A2 (es) 2022-01-17
MX2021011272A (es) 2021-10-01
IL286350A (en) 2021-10-31
EP3938354A4 (en) 2022-12-28
CR20210498A (es) 2022-01-11
SG11202109662YA (en) 2021-10-28
BR112021018295A2 (pt) 2021-11-23
EP3938354A2 (en) 2022-01-19
AU2020241703A1 (en) 2021-10-14
US20230115366A1 (en) 2023-04-13
CA3133688A1 (en) 2020-09-24
CN113811528A (zh) 2021-12-17
CN115215808A (zh) 2022-10-21
JP2024102094A (ja) 2024-07-30
US20220064177A1 (en) 2022-03-03
WO2020190765A2 (en) 2020-09-24
WO2020190765A3 (en) 2020-11-26
JP2022526266A (ja) 2022-05-24
SA521430328B1 (ar) 2024-03-28
KR20210151820A (ko) 2021-12-14
JP7474269B2 (ja) 2024-04-24

Similar Documents

Publication Publication Date Title
CL2021002409A1 (es) Composiciones y métodos para tratar el cáncer
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
PE20191303A1 (es) Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2
CL2019000819A1 (es) Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134)
CO2019004791A2 (es) Anticuerpo anti-gpr20 y conjugado de anticuerpo-medicamento anti-gpr20
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
TNSN08375A1 (en) Quinazolines for pdk1 inhibition
MA38959A1 (fr) Modulateurs du facteur b du complément
MX2017016071A (es) Terapia de combinacion para el tratamiento de cancer.
NI201000083A (es) Tratamiento de cáncer de mama con un compuesto de 4 - iodo - 3 - nitrobenzamida en combinación con agentes anti-tumorales.
CO6361927A2 (es) Quinazolinas para inhibicion de pdk1
PA8807801A1 (es) Inhibidores de cinesina como productos terapeuticos para el cancer
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
BR112015026257A2 (pt) terapia de combinação compreendendo um composto di-hidropirazino-pirazina e um antagonista do receptor de andrógeno para tratar câncer de próstata
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы
CO2024009571A2 (es) Inhibidores de parp1
EA201101651A1 (ru) Непрерывное введение интегриновых лигандов для лечения рака
CO2020013968A2 (es) Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer
ZA202301066B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
BR112017022296A2 (pt) métodos para tratar câncer
MX2023008375A (es) Composiciones farmacéuticas para tratar cánceres de mama y métodos de usos de estas.
WO2016187620A3 (en) Anti-cancer compounds
EA202192513A1 (ru) Композиции и способы для лечения рака
CO2019001967A2 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1